Nurix Therapeutics (NRIX) Operating Leases: 2021-2025
Historic Operating Leases for Nurix Therapeutics (NRIX) over the last 4 years, with Aug 2025 value amounting to $52.7 million.
- Nurix Therapeutics' Operating Leases rose 155.93% to $52.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $52.7 million, marking a year-over-year increase of 155.93%. This contributed to the annual value of $20.3 million for FY2024, which is 12.26% down from last year.
- Latest data reveals that Nurix Therapeutics reported Operating Leases of $52.7 million as of Q3 2025, which was up 12.85% from $46.7 million recorded in Q2 2025.
- In the past 5 years, Nurix Therapeutics' Operating Leases registered a high of $52.7 million during Q3 2025, and its lowest value of $2.6 million during Q3 2023.
- In the last 3 years, Nurix Therapeutics' Operating Leases had a median value of $20.6 million in 2024 and averaged $21.6 million.
- Per our database at Business Quant, Nurix Therapeutics' Operating Leases tumbled by 65.89% in 2023 and then skyrocketed by 679.33% in 2024.
- Quarterly analysis of 5 years shows Nurix Therapeutics' Operating Leases stood at $9.2 million in 2021, then dropped by 29.98% to $6.4 million in 2022, then soared by 259.42% to $23.1 million in 2023, then dropped by 12.26% to $20.3 million in 2024, then skyrocketed by 155.93% to $52.7 million in 2025.
- Its Operating Leases stands at $52.7 million for Q3 2025, versus $46.7 million for Q2 2025 and $20.0 million for Q1 2025.